Adial Pharmaceuticals, Inc. (ADIL) Stock Forecast
ADIL analyst forecast
as of October 17, 2026- Analyst consensus
- Buy 4.25 / 5 from 4 analysts
- Price target
- $8.33 average of analyst targets
- Upside to target
- +138.8% from the latest close
- Next earnings
- November 12, 2026
- 52-week range
- $1.36 – $9.44
ADIL analyst ratings
4 analystsNumber of analysts at each rating.
ADIL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ADIL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$2.58 | −$5.00 | −$0.15 | −$2.00 | −28.7% | 2 |
| Current fiscal year (2026) | −$1.05 | −$1.05 | −$1.05 | −$11.93 | +91.2% | 1 |
| Next fiscal year (2027) | −$7.45 | −$14.25 | −$0.65 | −$1.05 | −609.5% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ADIL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 1 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
ADIL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ADIL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.31 | −$1.16 | −$5.00 | −$5.00 | −$2.58 | +96.6% | 0 up · 0 down |
| Current fiscal year (2026) | −$6.12 | −$5.26 | $0.00 | $0.00 | −$1.05 | −82.8% | 1 up · 0 down |
| Next fiscal year (2027) | −$2.59 | −$2.49 | −$14.25 | −$14.25 | −$7.45 | +187.6% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ADIL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ADIL beat in 7 of 12.
What analysts expect from ADIL
4 analysts cover Adial Pharmaceuticals; their consensus rating is buy (4.25 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.33, 138.8% above the latest close of $3.49. Analysts expect earnings of −$1.05 per share for 2026, +91.2% from a year earlier. For 2027 the average estimate is −$7.45 per share. Adial Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: ADIL income statement, ADIL key metrics, ADIL chart. See the ADIL stock overview for the latest quote and news.
ADIL forecast FAQ
What is Adial Pharmaceuticals's price target?
The average analyst price target for Adial Pharmaceuticals is $8.33, 138.8% above the latest close of $3.49.
Is Adial Pharmaceuticals a buy, hold or sell?
Of 4 analysts covering Adial Pharmaceuticals, 2 rate it a strong buy, 1 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Adial Pharmaceuticals's EPS forecast?
Analysts forecast −$1.05 per share for 2026 (range −$1.05 to −$1.05); for 2027 the estimate is −$7.45.
When does Adial Pharmaceuticals report earnings?
Adial Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
Does Adial Pharmaceuticals usually beat earnings estimates?
Adial Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.